Literature DB >> 3472488

Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects.

S L Gregoire, T H Grasela, J P Freer, K J Tack, J J Schentag.   

Abstract

The influence of multiple doses of ofloxacin (ORF 18489) on the disposition of theophylline was studied in 15 male volunteers. Subjects were confined in the Clinical Research Unit for 13 days and given a xanthine-free diet. A single dose (3 mg/kg) of theophylline was given orally, and blood samples were collected at fixed time intervals for 36 h. The concentrations of theophylline were measured with TDX (Abbott Diagnostics, Irving, Tex.), and clearance was calculated. Theophylline clearance was used to individualize subsequent doses to achieve average steady-state theophylline concentrations in plasma of 10 mg/liter. Individualized theophylline doses were administered every 8 h until steady-state conditions were reached. Theophylline clearance was determined again at steady state and on days 7 and 8. On day 8, ofloxacin (400 mg every 12 h) was given concomitantly with theophylline. Theophylline clearance was measured again on day 12, after the last theophylline dose. Administration of ofloxacin for 1 day did not change theophylline clearance, but coadministration for 4 days significantly decreased theophylline clearance by 12.1% (P less than 0.05). The area under the concentration-time curve for theophylline increased 9.9% (P less than 0.05), and average steady-state concentrations in plasma increased 10.3% (P less than 0.05). Despite changes in clearance, adverse effects of theophylline did not increase during coadministration of ofloxacin. Although statistically significant, the interaction between ofloxacin and theophylline is unlikely to be of major clinical importance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472488      PMCID: PMC174735          DOI: 10.1128/AAC.31.3.375

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Convulsions and hyperglycaemia associated with nalidixic acid.

Authors:  A G Fraser; A D Harrower
Journal:  Br Med J       Date:  1977-12-10

2.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

3.  Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.

Authors:  W J Jusko; M J Gardner; A Mangione; J J Schentag; J R Koup; J W Vance
Journal:  J Pharm Sci       Date:  1979-11       Impact factor: 3.534

4.  [Neurologic side effects of quinolones].

Authors:  M C Galland; M H Jouve-Bestagne; F Rodor; J Jouglard
Journal:  Therapie       Date:  1982 Jul-Aug       Impact factor: 2.070

5.  Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

Authors:  M Tsukamura; E Nakamura; S Yoshii; H Amano
Journal:  Am Rev Respir Dis       Date:  1985-03

6.  Alteration of theophylline clearance and half-life by cimetidine in normal volunteers.

Authors:  D P Reitberg; H Bernhard; J J Schentag
Journal:  Ann Intern Med       Date:  1981-11       Impact factor: 25.391

7.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

8.  The pharmacokinetics and tissue penetration of ofloxacin.

Authors:  M R Lockley; R Wise; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

Review 9.  Theophylline. A "state of the art" review.

Authors:  L Hendeles; M Weinberger
Journal:  Pharmacotherapy       Date:  1983 Jan-Feb       Impact factor: 4.705

10.  In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280).

Authors:  M Tsukamura
Journal:  Am Rev Respir Dis       Date:  1985-03
View more
  20 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.

Authors:  A Anadón; M R Martinez-Larrañaga; M C Fernandez; M J Diaz; P Bringas
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 4.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 5.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Effect of norfloxacin on theophylline metabolism.

Authors:  R L Davis; H W Kelly; R W Quenzer; J Standefer; B Steinberg; J Gallegos
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

7.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats.

Authors:  T Hasegawa; M Nadai; S Haghgoo; K Yamaki; K Takagi; T Nabeshima
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

9.  Effect of norfloxacin on theophylline pharmacokinetics at steady state.

Authors:  S K Bowles; Z Popovski; M J Rybak; H B Beckman; D J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.